---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-209160"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:23:54.199415+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CalciMedica Q2 net loss $6.3M, cash $19.1M; Auxora Phase 2b expands to India, AKI IND expected by year-end

## Summary
- Net loss $6.3M ($1.11/sh) in Q2 2023; cash $19.1M expected to fund operations for at least 12 months.
- CARPO Phase 2b trial of Auxora in acute pancreatitis with SIRS expanded to India; enrollment complete expected Q1 2024, topline data H1 2024.
- IND filing for Auxora in acute kidney injury expected by year-end 2023; trials could begin H1 2024 pending additional funding.
- Appointed Raven Jaeger as Chief Regulatory Officer and Andrew Cunningham as SVP Clinical Development; stock relisted on Nasdaq in June.
- Preclinical data in JCI Insight show Orai1 inhibition prevents progression of recurrent acute pancreatitis and early chronic pancreatitis.

## SEC filing metadata
- accession: 0001193125-23-209160
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/0001193125-23-209160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/d477357d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-209160
- JSON: https://secwatch.observer/filing/0001193125-23-209160.json
- Plain text: https://secwatch.observer/filing/0001193125-23-209160.txt

## Key facts
- Earnings Releases
  CalciMedica, Inc. reported three months ended June 30, 2023 results: net income $6.3 million, or $1.11 per share (basic and diluted), EPS $1.11 per share (basic and diluted).
  - Period: three months ended June 30, 2023
  - Net income: $6.3 million, or $1.11 per share (basic and diluted)
  - EPS: $1.11 per share (basic and diluted)
  - Result: reported results
  source text: Net loss was $6.3 million, or $1.11 per share (basic and diluted), and $25.6 million, or $7.86 per share (basic and diluted), for the three and six months ended June 30, 2023, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/0001193125-23-209160-index.htm
- Shareholder Votes
  CalciMedica, Inc. shareholders approved Election of Class III Directors at the 2023-08-09 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-08-09
  source text: Proposal 1. Election of Class III Directors The Company’s stockholders elected the two persons listed below as Class III directors, each to serve a three-year term through the Company’s 2026 annual meeting of stockholders and until a successor has been elected and qualified or until earlier resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/0001193125-23-209160-index.htm
- Shareholder Votes
  CalciMedica, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-08-09 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-08-09
  source text: Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s principal independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534133/000119312523209160/0001193125-23-209160-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.